DNMT3A and hydrops fetalis: Moreover, patients carrying DNMT3A or TET2 mutations experienced substantially worse long-term outcomes, including higher rates of mortality and HF-related hospitalization, with greater mutational burden correlating with progressively adverse prognosis [59].